KNIGHT, Andrea, Pavla VŠIANSKÁ, Martin PISKACEK, Pavel NĚMEC, Luděk POUR, Zdeněk ADAM a Roman HÁJEK. Interactions of plasmacytoid dendritic cells with myeloma plasma cells and gamma/delta T cells in MGUS and multiple myeloma patients. In ESH International Conference on Multiple Myeloma, Dublin, Ireland. 2013.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Interactions of plasmacytoid dendritic cells with myeloma plasma cells and gamma/delta T cells in MGUS and multiple myeloma patients
Autoři KNIGHT, Andrea, Pavla VŠIANSKÁ, Martin PISKACEK, Pavel NĚMEC, Luděk POUR, Zdeněk ADAM a Roman HÁJEK.
Vydání ESH International Conference on Multiple Myeloma, Dublin, Ireland, 2013.
Další údaje
Originální jazyk angličtina
Typ výsledku Konferenční abstrakt
Obor 30200 3.2 Clinical medicine
Stát vydavatele Irsko
Utajení není předmětem státního či obchodního tajemství
Organizační jednotka Lékařská fakulta
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 9. 1. 2014 10:09.
Anotace
Objectives: It is well accepted that the bone marrow microenvironment and the tumour-associated milieu of cell interactions plays a significant role in Multiple Myeloma (MM). However, the role of innate effector gamma/delta T cells in patients progressing from monoclonal gammopathy of undetermined significance (MGUS) to MM in this process is unknown. We have recently shown that Vdelta1 gamma/delta T lymphocytes isolated from myeloma patients exert specific cytotoxicity against primary CD38+CD138+ bone marrow derived plasma cells (Knight et al., Cytotherapy 2012). Large expansions of Vdelta1 gamma/delta T cells have been observed in MM patients suggesting their direct involvement in anti-myeloma immune responses. We hypothesized that the expansions of Vdelta1 gamma/delta T cells are driven by the cell interactions with plasmacytoid dendritic cells (pDC) within the bone marrow microenvironment. Methods: We have used fresh whole bone marrow (BM) and paired peripheral blood (PB) samples from MGUS (n=6) and newly diagnosed myeloma patients (n=21) to determine the frequencies of CD123+CD304+ pDC and Vdelta1 and Vdelta2 gamma/delta T cells by multicolour flow cytometry. Results: In MGUS patients, the median levels of Vdelta1 and Vdelta2 cells in the BM were 2.19 (range 0.55-8.05) and 0.63 (0.04-10.2) of CD3+ T cells respectively. Largely expanded levels of pDCs with CD45RA+HLA-DR+ phenotype were detected in MGUS patients in BM compared to healthy BM controls (n=4). In contrast, in newly diagnosed MM patients, the frequencies of pDCs were significantly reduced compared to MGUS patients (p<0.0001) or normal BM (p=0.0023). PB-derived pDC from MGUS or MM patients were numerically within the normal PB range (n=9). Conclusions: Our results show significantly elevated frequencies of Vdelta1 gammadelta T cell subset in patients progressing from MGUS to MM. In parallel, expanded levels of pDCs detected in the BM are believed to be driving the Vdelta1 gamma/delta T cell expansions. Further analyses of the key interactions between the target and effector cells through functional studies, gene expression profile and microarray analyses in patient cohorts will be discussed. Together, we provide evidence for the use of Vdelta1 gamma/delta T cells as a new mode of myeloma immunotherapy.
Návaznosti
MSM0021622415, záměrNázev: Molekulární podstata buněčných a tkáňových regulací
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Molekulární podstata buněčných a tkáňových regulací
MUNI/11/InGA07/2012, interní kód MUNázev: Analýza cytomegalovirové reaktivity efektorových gamma-delta buněk u zdravých jedinců
Investor: Masarykova univerzita, Analýza cytomegalovirové reaktivity efektorových gamma-delta buněk u zdravých jedinců
NT14310, projekt VaVNázev: Buněčné stárnutí u hematoonkologických onemocnění
Investor: Ministerstvo zdravotnictví ČR, Buněčné stárnutí u hematoonkologických onemocnění
3SGA5924, interní kód MUNázev: Investigations of human gamma-delta T cells: a new candidate for novel antiviral and antitumour immunotherapy (Akronym: Gammadelta T cells)
Investor: Jihomoravský kraj, Investigations of human gamma-delta T cells: a new candidate for novel antiviral and antitumour immunotherapy, Reintegrační granty
VytisknoutZobrazeno: 22. 8. 2024 14:10